Stockscreener 앱 받기
42.31
1.74%
-0.75
시간 외 거래:
41.50
-0.81
-1.91%
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools - The Motley Fool
VR Adviser Increases Spyre Therapeutics Investment to $120.74MNews and Statistics - IndexBox
Signal or Noise: How VR Adviser's Acquisition of Spyre Therapeutics Impacts Fools - Bitget
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools - The Motley Fool
SYRE Stock Gets a Boost: Stifel Raises Price Target to $92 | SYR - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $92.00 - MarketBeat
Stifel raises Spyre stock price target to $92 on TL1A potential - Investing.com Canada
Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms (NASDAQ:SYRE) - Seeking Alpha
Spyre Therapeutics (SYRE) Is Up 7.3% After Accelerating SPY072 Phase 2 POC TimelineHas The Bull Case Changed? - simplywall.st
BTIG Reiterates Buy Rating for Spyre Therapeutics (SYRE) with $7 - GuruFocus
Spyre Therapeutics (SYRE) Advances RA Sub-Study with Early Resul - GuruFocus
Leerink Maintains Outperform on Spyre Therapeutics, Inc. (SYRE) March 16, 2026 - Meyka
Deutsche Bank Raises Price Target for Spyre Therapeutics on Strong Cash Position - timothysykes.com
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 9.3%Should You Buy? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Given Buy Rating at BTIG Research - MarketBeat
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 - Bitget
RA sub-study patient enrollment ends in Phase 2 SKYWAY trial as Spyre Therapeutics, Inc. eyes data release - Traders Union
Spyre Therapeutics, Inc. $SYRE Shares Acquired by HighVista Strategies LLC - MarketBeat
Aug Spikes: Can Spyre Therapeutics Inc lead its sector in growthRate Cut & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Baker BROS. Advisors LP Buys 373,297 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - AOL.com
Transcript : Spyre Therapeutics, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08 - marketscreener.com
Market Review: Is RBNE stock risky to hold now2026 Fundamental Recap & Safe Entry Point Identification - baoquankhu1.vn
DLD Asset Management LP Acquires New Position in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Weekly Earnings: What is the implied volatility of Spyre Therapeutics IncMarket Activity Recap & Community Driven Trade Alerts - baoquankhu1.vn
Patterns Watch: Can Spyre Therapeutics Inc grow without external fundingMarket Trend Review & Technical Confirmation Trade Alerts - baoquankhu1.vn
Trading Recap: Can Spyre Therapeutics Inc deliver consistent EPS growthVolume Spike & Weekly Top Performers Watchlists - baoquankhu1.vn
New Spyre hires get 46,600 stock options at $42.49 strike - Stock Titan
[EFFECT] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Assessing Spyre Therapeutics (SYRE) Valuation After A Year Of Strong Shareholder Returns - Yahoo Finance
Insider Selling: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE) - GuruFocus
Scott Burrows Sells 2,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $632,850.00 in Stock - MarketBeat
Spyre Therapeutics (SYRE) CFO sells 2,500 shares under 10b5-1 plan - Stock Titan
Investment Review: Is Spyre Therapeutics Inc a top pick in the sectorPortfolio Return Report & Verified Entry Point Signals - baoquankhu1.vn
Spyre Therapeutics CEO Sells 15,000 Shares - TradingView
Support Test: Can Spyre Therapeutics Inc lead its sector in growthPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Morgan Stanley broker lists 60,000-share SYRE resale (SYRE) - Stock Titan
SYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SYRE PE Ratio & Valuation, Is SYRE Overvalued - Intellectia AI
Spyre Therapeutics, Inc. (SYRE): Investor Outlook Amid A 35% Potential Upside - DirectorsTalk Interviews
[POS AM] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics, Inc. targets breakthrough in inflammatory bowel disease with combination therapies - Traders Union
Spyre reports enhanced efficacy of anti-TL1A and anti-IL-23 combination - BioWorld MedTech
Assessing Spyre Therapeutics (SYRE) Valuation After A Powerful Multi‑Period Share Price Run - simplywall.st
Insider Sell: Can Spyre Therapeutics Inc maintain sales growthTrade Risk Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Spyre Therapeutics to Participate in Upcoming March Investor Conferences - Bitget
Bull Bear: Is Spyre Therapeutics Inc a top pick in the sector2025 Pullback Review & Weekly Top Performers Watchlists - baoquankhu1.vn
SYRESpyre Therapeutics Latest Stock News & Market Updates - Stock Titan
Biotech Spyre lines up Boston and Miami investor talks in March - Stock Titan
Deutsche Bank Adjusts Spyre Therapeutics PT to $55 From $45, Maintains Buy Rating - marketscreener.com
1.20%
0.06%
자본화:
|
볼륨(24시간):